重组人表皮细胞生长因子缓释微球治疗糖尿病大鼠溃疡

目的 制备重组人表皮细胞生长因子(rhEGF)缓释微球,并对其形貌、释药行为和在体外促进细胞增殖的能力进行评价;同时比较rhEGF缓释微球与rhEGF原液对糖尿病大鼠溃疡促愈作用的差异. 方法 (1)用改进的复乳法制备rhEGF缓释微球.透射电镜检测rhEGF微粒形貌表征,激光粒度仪/Zeta电位仪分析微球粒径分布,ELISA法测定rhEGF微球释药行为.(2)以小鼠成纤维细胞L929细胞系为对象,采用MTT法鉴定rhEGF缓释微球的生物学活性.(3)制备糖尿病大鼠溃疡模型,成模后采用随机数字表法将大鼠分为4组:rhEGF缓释微球组(A组)、rhEGF原液组(B组)、空白微球组(C组)、PBS溶媒对照组(D组),每天给药1次.分别于给药后3,7,14,21 d对溃疡创面照相计算创面愈合率.创缘皮肤取材,测定羟脯氨酸含量,免疫组化检测β1整合素和角蛋白-19并测量其阳性染色面积比. 结果 (1)rhEGF缓释微球平均粒径为193.5nm,粒径分布均匀,微球之间元粘连,分散性好.释药过程符合Higuchi释放动力学模型,释放时间长达24 h.(2)不同浓度rhEGF缓释微球均有促进小鼠成纤维细胞增殖的作用,其中以10μg/L浓度促小鼠成纤维细胞增殖的作用最强.(3)从治疗第7天开始,愈合率以A组最快,A组与其他三组比较,差异均有统计学意义(P<0.05).羟脯氨酸含量、β1整合素和角蛋白-19阳性染色面积比A组均高于B组. 结论 用改进的复乳法制备的rhEGF缓释微球,粒径大小分布均一,释放时间长达24 h.rhEGF缓释微球促进糖尿病大鼠溃疡创面愈合速度较rhEGF原液更快,溃疡创面愈合质量更高.

Repair of ulcer with rhEGF sustained-release microspheres in diabetic rats

Objective To prepare recombinant human epidermal growth factor (rhEGF) sustained-release microspheres and evaluate their morphology, rhEGF releasing activities and cell proliferation activity in vitro and compare difference of rhEGF sustained-release microspheres and rhEGF in facilitaring ulcer healing in diabetic rats. Methods (1) rhEGF sustained-release microspheres were prepared by the modified double emulsion method. Morphology of the microspheres was detected by transmission electron microscope and size distribution measured by laser granularity meter/Zeta electric potential meter. ELISA assays were applied to determine rhEGF releasing. (2)Proliferation of mouse fibroblasts was analyzed by MTr method. (3) Diabetic rat models were prepared and divided into four groups, ie, rhEGF sustained-release mierospheres group (Group A), rhEGF stock solution group (Group B), blank sustainedrelease mierospheres group (Group C) and PBS meustruum control group (Group D), which were given drug once a day. The wound healing rate was calculated by taking photographs at days 3,7,14 and 21. Skin specimens from the wound edge were harvested partially for observation of hydroxyproline (HYP) contents. Immunohistochemistry was employed to detect integrin 131 and keratin-19 and measure their positive staining area ratio. Results (1) The particle diameter of rhEGF sustained-release microspheres was 193.5 nm, with relative uniform particle diameter distribution. There showed no conglutination among rhEGF susrained-release microspheres, with good dispersibility. Releasing drug lasted for 24 hours and accorded with Higuchi release kinetic model. (2) Different concentrations of rhEGF sustained-release microspheres could promote the proliferation of mouse fibroblast, especially the concentration of 10 μg/L (P <0.05, compared with the control). (3) From the 7th day after treatment, Group A had the fastest wound healing rate, with statistical difference compared with other three groups (P < 0.05). Group A had higher HYP contents and positive area ratio of integrin β1 and keratin-19 than Group B. Conclusions rhEGF sustained-release microspheres prepared by the modified double emulsion method have uniform particle size and can last release for 24 hours. Compared with rhEGF stock solution, rhEGF sustained-release microspheres have faster and better ulcer healing and higher healing quality in diabetic rats.